E. M. Delemarre

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

M. D. de Bruin‐Weller, M. Schuttelaar, E. Knol, 2019, Allergy.